Moovartes SRL
8.4 FTEMoovartes reported total assets of €3.16m at the end of the 2025 financial year (annual accounts filed with the NBB on 20 Feb 2026), with 8.4 full-time equivalents.
The score of Moovartes shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -70 % Total assets -44 % Headcount (avg FTE) -10 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Moovartes's annual accounts
Filed annual accounts
- Year ended 30 Sep 2025filed on 20 Feb 2026
- Year ended 30 Sep 2024filed on 31 Mar 2025
- Year ended 30 Sep 2023filed on 18 Jan 2024
- Year ended 30 Sep 2022filed on 06 Jun 2023
- Year ended 30 Sep 2021filed on 17 Mar 2022
Moovartes's financial analysis
- Solvency47.1%sector median: 46.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Moovartes
Moovartes's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0433.793.403
- VAT number
- BE0433793403
- Peppol
- Registered · 0208:0433793403 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 18 Mar 1988
- Registered office
- 3600 Genk
- Size
- Micro · 8.4 FTE
- Latest accounts
- 2025 · filed on 20 Feb 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Moovartes (SRL) has been based in Genk since 1988, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of 899,121 € and equity of €1.49m; its revenue is not published. With 8.4 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 47.1%, above the median of its sector (46.0%).
Companies similar to Moovartes
Companies in the same business, of comparable size and area, outside its group.
- P&R Medical Wholesale of pharmaceutical and medical goods Diepenbeek · balance sheet €3.43m
- ZimVie Belgium Wholesale of pharmaceutical and medical goods Aarschot · balance sheet €2.19m
- Endoceutics Wholesale of pharmaceutical and medical goods Brussels · balance sheet €3.45m
- Launchpad Europe Wholesale of pharmaceutical and medical goods Oostkamp · balance sheet 120,635 €
- Maimonides Wholesale of pharmaceutical and medical goods Antwerp · balance sheet 142 €
- Biocon Biologics Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €1.09m
- Wimeq Wholesale of pharmaceutical and medical goods Heusden-Zolder · balance sheet 48,978 €
- MiniMed Belgium Wholesale of pharmaceutical and medical goods Brussels · balance sheet 8,076 €
Frequently asked questions about Moovartes
What is the revenue of Moovartes?
Moovartes files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Moovartes?
In Belgium, the VAT number is the company number prefixed with BE: BE0433793403 for Moovartes, if the company is VAT-registered. Its company number (CBE) is 0433.793.403.
Where is the registered office of Moovartes?
According to the CBE register, the registered office of Moovartes is in 3600 Genk.
What is the equity of Moovartes?
At the close of the 2025 financial year, the equity of Moovartes amounts to 1,488,017 €, a solvency of 47.1% of total assets.
How many people work at Moovartes?
8.4 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Moovartes?
The register lists 2 active mandates at Moovartes. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Moovartes
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →